Adagene Inc (ADAG) Live Share Price, Invest From India

Adagene Inc Stock Performance

as on May 19, 2026 at 2:29 am IST

Day's High
$3.43
Day's Price Range
$3.50
$3.43
2.04%
Upside
52 Week's Low
52 Week's High
$1.30
52-Week Price Range
$4.75
$3.43
62.10%
Downside
38.48%
Upside

Adagene Inc share price movements today

Previous Close: $3.50
Open: $3.49
Volume: 16.4K
Day's Low - High: $3.43 - $3.50
52 Week Low - High: $1.30 - $4.75

Adagene Inc Historical Returns

1 Month Return: -11.84 %
3 Month Return: + 6.38 %
1 Year Return: + 97.74 %
3 Year Return: + 132.14 %
5 Year Return: 0 %

Adagene Inc Stock Fundamentals & Key Indicators

Check Adagene Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$241.8M

EPS (TTM)

-0.51

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-21.0M

Revenue (TTM)

7.7M

Profit Margin

-229.56%

Return On Equity TTM

-34.39%

Adagene Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Adagene Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Adagene Inc	BUY	$241.8M	NA	NA	-229.56%
Revolution Medicines Inc	BUY	$31.8B	341.26%	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$39.2B	112.34%	73.55	12.55%
Vertex Pharmaceuticals Inc	BUY	$115.0B	103.57%	26.89	35.51%
Regeneron Pharmaceuticals Inc	BUY	$74.7B	35.26%	17.39	29.65%

Stock Returns calculator for Adagene Inc Stock including INR - Dollar returns

The Adagene Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Adagene Inc investment value today

Current value as on today

₹2,18,624

Returns

₹1,18,624

(+118.62%)

Returns from Adagene Inc Stock

₹93,785 (+93.79%)

Dollar Impact

₹24,839 (+24.84%)

Analyst Recommendation on Adagene Inc Stock

Based on 8 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 8 analysts, 87.5% of analysts recommend a 'BUY' rating for Adagene Inc. Average target price of $9.4

Adagene Inc Share Price Target

Get share price movements and forecasts by analysts on Adagene Inc.

What analysts predicted

63.51%UPSIDE

Target Price

$9.4

Current Price

$3.43

Analyzed by

8 Analysts

Target

$9.40

Adagene Inc target price $9.4, a slight upside of 63.51% compared to current price of $3.43. According to 8 analysts rating.

Indian Investors' Interest in Adagene Inc Stock

Search interest for Adagene Inc Stock has increased by 133% in the last 30 days, reflecting an upward trend in search activity.

Time period: April 18, 2026 to May 18, 2026

Change:133% versus previous 30 day period

Adagene Inc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Dec 2024	Mar 2026
Total Revenue	8	8	0	0	0	7
Gross Profit	8	8	0	0	0	7
Operating Income	-2	-2	-9	-9	-26	-5
EBITDA	-2	-2	-9	-9	-22	-5
Interest Expense	0	0	-	0	0	0
Depreciation	-	-	-	-	-	-
Income Before Tax	0	0	-7	-7	-24	-4
Income Tax Expense	1	1	0	0	0	0
Net Income	-2	-2	-7	-7	-24	-4
Net Profit Margin	-23.76%	-23.76%	-1818.90%	-1818.90%	-24144.66%	-53.87%

Adagene Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	1	0	0	10	9	18	0	7
Gross Profit	1	0	0	10	9	18	0	7
Operating Income	-17	-19	-19	-72	-83	-23	-35	-21
EBITDA	-14	-15	-41	-69	-77	-14	-31	-16
Interest Expense	0	0	0	0	0	1	0	0
Depreciation	0	0	0	1	1	1	0	0
Income Before Tax	-15	-16	-16	-71	-79	-17	-33	-17
Income Tax Expense	0	0	0	1	0	1	0	0
Net Income	-14	-17	-16	-73	-79	-18	-33	-17
Net Profit Margin	-974.03%	-3602.89%	-3424.06%	-719.18%	-860.59%	-104.61%	-32386.45%	-229.56%

Adagene Inc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Jun 2025	Mar 2026
Net Income	-2	-7	-7	-8	-8	-8	-24	-13	-4
Operating Cash Flow	-6	-	-	-6	-6	-6	-23	-11	-4
Investing Cash Flow	0	-	-	0	-	0	0	0	0
Financing Cash Flow	0	-	-	0	0	-1	5	-11	16
Change in Cash	-14	-	-	-7	-7	-7	-10	-22	11

Adagene Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-16	-42	-73	-79	-18	-33	-17
Operating Cash Flow	-18	-28	-43	-48	-28	-29	-15
Investing Cash Flow	24	7	-2	0	0	1	0
Financing Cash Flow	69	4	145	17	-5	3	4
Change in Cash	76	-17	99	-30	-33	-24	-10

Global Institutional Holdings in Adagene Inc

Funds	Holdings
BNP Paribas Arbitrage, SA	0%
Barclays PLC	0.39%
BlackRock Inc	0%
SBI Securities Co Ltd	0%
XTX Topco Ltd	0%

See all

Insights on Adagene Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 103.20K → 7.69M (in $), with an average increase of 98.7% per quarter
POSITIVE IMPACT
Price Rise
In the last 6 months, ADAG stock has moved up by 76.5%
POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, -24.91M → -4.14M (in $), with an average increase of 155.2% per quarter
NO EFFECT
Against Peers
In the last 1 year, Revolution Medicines, Inc. Common Stock has given 268.4% return, outperforming this stock by 170.7%
NO EFFECT
Against Peers
In the last 3 years, Revolution Medicines, Inc. Common Stock has given 473.9% return, outperforming this stock by 341.8%

About Adagene Inc

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Organisation	Adagene Inc
Headquarters	Building C14, Suzhou, China, 215123
Industry	Biotechnology
CEO	Dr. Peter P. Luo Ph.D.
E-voting on shares	Click here to vote

Key Management of Adagene Inc

Name	Title
Dr. Peter P. Luo Ph.D.	Co- Founder, Chairman, CEO and President of R&D
Mr. Man Kin Tam M.B.A.	CFO & Director
Mr. Mickael Chane-Du	Chief Strategy Officer
Ms. Yan Li M.B.A.	Senior Vice President of Bioinformatics & Information Technology
Mr. Alexander Goergen	VP & Head of Business Development
Ms. Ling Zhou	Executive Director & Head of Human Resources
Dr. Qinghai Zhao Ph.D.	Chief Manufacturing Officer
Ms. Chunfang Gu	Executive Director of Finance
Ms. Xiaohong She	Senior VP & Head of Clinical Operations
Dr. Guizhong Liu Ph.D.	Senior Vice President of Early Drug Discovery

FAQs

What is Adagene Inc share price today?

Adagene Inc share price today is $3.43 as on May 18, 2026 at 8:59 pm IST. Adagene Inc share today touched a day high of $3.5 and a low of $3.43.

What is the 52 week high and 52 week low for Adagene Inc share?

Adagene Inc share touched a 52 week high of $4.75 on April 7, 2026 and a 52 week low of $1.3 on November 7, 2025. Adagene Inc stock price today i.e. May 18, 2026 at 8:59 pm IST is trending at $3.43,which is 27.79% down from its 52 week high and 163.85% up from its 52 week low.

What is Adagene Inc's market capitalisation today?

Adagene Inc market capitalisation is $0.00T as on May 18, 2026 at 8:59 pm IST.

How to invest in Adagene Inc Stock (ADAG) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Adagene Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Adagene Inc Shares that will get you 0.4373 shares as per Adagene Inc share price of $3.43 per share as on May 18, 2026 at 8:59 pm IST.

What is the minimum amount required to buy Adagene Inc Stock (ADAG) from India?

Indian investors can start investing in Adagene Inc (ADAG) shares with as little as ₹96.335 or $1 (as of May 18, 2026 at 9:03 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹963.35 in Adagene Inc stock (as per the Rupee-Dollar exchange rate as on May 18, 2026 at 9:03 pm IST). Based on Adagene Inc share’s latest price of $3.43 as on May 18, 2026 at 8:59 pm IST, you will get 2.9155 shares of Adagene Inc. Learn more about fractional shares .